drugset / Trial / NCT02678767

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

NCT02678767

Non-randomizedSingle-groupOpen-labelScreening

Summary

This project will investigate the ability of a novel MRI contrast agent to identify and quantitate ongoing monocyte/macrophage (M/MΦ)-mediated inflammation in the brains of HIV-infected individuals.

Timeline

Start
2015-02
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent 4 mg/kg Intravenous

Indications